Idera begins state of matter II plaque psoriasis legal proceeding Pharmaceutical Business Review Idera Pharmaceuticals has initiated state of matter II trial of IMO-3100, the Toll-like receptor (TLR) inhibitor for the attention of autoimmune diseases, in patients with moderate to severe plaque psoriasis . IMO-3100 is an immunomodulator that inhibits the ... and more » Link To Article
No comments:
Post a Comment